Amgen Inc. which can be found using ticker (AMGN) now have 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $345.00 and $185.00 and has a mean share price target at $285.09. (at the time of writing). Given that the stocks previous close was at $300.69 this now indicates there is a potential downside of -5.2%. The 50 day moving average now sits at $273.17 and the 200 day moving average is $251.54. The total market capitalization for the company now stands at 162.25B. The stock price for the company is currently $303.17 USD
The potential market cap would be $153,832,281,323 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.37, revenue per share of $50.16 and a 7.86% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
